Endomagnetics and one of its founders has picked up a major accolade by being recognised in the Science Business Academic Enterprise Awards (ACES).
[Read more...]

Endomagnetics has announced achieving CE approval for the sale of its magnetic tracer material, branded Sienna+™.
[Read more...]

Endomagnetics has announced two key appointments as it expands in its new Cambridge base. Dr Andrew Shawcross has been appointed Director Operations and Dr Quentin Harmer is the new Director Technology. Both appointments are with immediate effect.
[Read more...]

Endomagnetics has announced raising additional funding, taking the sum raised in the last few months to £1.8 million ($2.9 million). The Company has also announced a move to Cambridge as it expands its operations.
[Read more...]

Endomagnetics has announced closing a funding round worth £1.2 million ($2 million) that provides a strong boost to the capabilities of the company and the commercialisation of its technology.
[Read more...]

Endomagnetics has announced the appointment of Dr John Gonzalez as Chairman. Dr Gonzalez brings with him a wealth of experience in healthcare and life sciences in business development, and latterly a successful career in medtech investment.
[Read more...]

Endomagnetics enjoyed successful participation in the Future Health Mission 2011 to San Francisco. The Mission took place January 8 – 14, 2011 and was organised to explore opportunities for growth with potential partners as well as customers, key investors, media and other stakeholders in Silicon Valley.

Alongside a series of meetings with clinicians, investors and supply chain partners, Endomagnetics received significant media coverage. [Read more...]

Endomagnetics generated huge interest in its innovative magnetic sensor technology when it exhibited at the 33rd Annual San Antonio Breast Cancer Symposium. Visitors to its booth were able to see two working models of the latest SentiMag™ product, and the company demonstrated the device to over 100 surgeons and oncologists from around the globe. They also saw a clinical video from the first sentinel lymph node biopsy (SLNB) with the SentiMag™ at Guy’s and St Thomas’ Hospitals, London. [Read more...]

Endomagnetics has today announced that it has achieved ‘CE Mark’ approval for its SentiMag™ product – a new surgical instrument used to locate lymph nodes in the treatment of cancer. This approval certifies that the product has met EU safety, health and environmental requirements, and clears the way for its adoption by clinicians across Europe.

The SentiMag™ is an ultrasensitive hand-held probe that is capable of detecting magnetic materials in the human body. The use of the SentiMag™ in conjunction with magnetic tracers eliminates the need for radioactive materials and dramatically extends the availability of sentinel lymph node biopsy (SLNB) in breast cancer staging. [Read more...]

Endomagnetics, the company pioneering the use of magnetic sensors for cancer staging and treatment, has been selected as one of twenty UK companies to take part in the upcoming Future Health Mission 2011 to the USA.

The Mission takes place in San Francisco between January 8th and 14th 2011, and is set up to explore opportunities for the participant companies for growth with potential partners as well as customers, key investors, media and other stakeholders in Silicon Valley. [Read more...]